Alyeska Investment Group
TVRD

Alyeska Investment Group’s Tvardi Therapeutics TVRD Stock Holding History

Alyeska Investment Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,147
Closed -$590K – 473
2015
Q3 		$590K Buy
+1,147
New +$768K 0.01% 421

Other funds holding TVRD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return

Alyeska Investment Group's TVRD Position: Q4 2015 in Review

Alyeska Investment Group sold out of Tvardi Therapeutics (TVRD) in Q4 2015, closing a stake of 1,147 shares — an estimated $590K sold.

Alyeska Investment Group first reported a position in TVRD in Q3 2015 and held it in 1 quarter. The position peaked at $590K in Q3 2015. 95 funds tracked by Wall St. Rank hold TVRD as of Q4 2015.

  • Alyeska Investment Group reported no remaining Tvardi Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 1,147 Tvardi Therapeutics shares in Q4 2015, an estimated $590K.
  • Alyeska Investment Group first reported a position in Tvardi Therapeutics in Q3 2015 and held it in 1 quarter.
  • Alyeska Investment Group's Tvardi Therapeutics position peaked at $590K in Q3 2015.
  • 95 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2015.

Based on Alyeska Investment Group's 13F filing for Q4 2015, filed 16 Feb 2016.